A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
Journal
British journal of cancer
Journal Volume
129
Journal Issue
6
Date Issued
2023-10
Author(s)
Macaulay, Valentine M
Lord, Simon
Hussain, Syed
Maroto, José Pablo
Jones, Robert Hugh
Climent, Miguel Ángel
Cook, Natalie
Wang, Shian-Shiang
Bianchini, Diletta
Bailey, Mark
Schlieker, Laura
Bogenrieder, Thomas
de Bono, Johann
Abstract
This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC).
SDGs
Type
journal article